Anticancer agents - JA - Lecture 6 - clean (1).pptx

28 May 2023
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
Anticancer agents - JA - Lecture 6 - clean (1).pptx
1 sur 12

Contenu connexe

Similaire à Anticancer agents - JA - Lecture 6 - clean (1).pptx

DNA, chromosomes and genomes NotesDNA, chromosomes and genomes Notes
DNA, chromosomes and genomes NotesYi Fan Chen
Histone proteinHistone protein
Histone proteinPrakash Pokhrel
Nucleosome and histonesNucleosome and histones
Nucleosome and histonesHARINATHA REDDY ASWARTHA
ChemotherapyChemotherapy
Chemotherapydas nelaturi
Chromatin Structure2015.pptChromatin Structure2015.ppt
Chromatin Structure2015.pptkhushbupriya2
Definition of epigeneticsDefinition of epigenetics
Definition of epigeneticsPeyman Ghoraishizadeh

Dernier

CASE STUDY ON OSTEOARTHRITISCASE STUDY ON OSTEOARTHRITIS
CASE STUDY ON OSTEOARTHRITISAnilDhakal14
Management of polytrauma.pptxManagement of polytrauma.pptx
Management of polytrauma.pptxM. Taqi Ehsani
The Potential of Medical Data Analytics.pdfThe Potential of Medical Data Analytics.pdf
The Potential of Medical Data Analytics.pdfHybrid Chartus
GAMMA KNIFE.pdfGAMMA KNIFE.pdf
GAMMA KNIFE.pdfKrishan Murari
MYOCARDIAL INFRACTION CASE REPORT.pptxMYOCARDIAL INFRACTION CASE REPORT.pptx
MYOCARDIAL INFRACTION CASE REPORT.pptxAnilDhakal14
KNOBOLOGY FOR ECHOCARDIOGRAM.pptxKNOBOLOGY FOR ECHOCARDIOGRAM.pptx
KNOBOLOGY FOR ECHOCARDIOGRAM.pptxAparanji Gopidi

Anticancer agents - JA - Lecture 6 - clean (1).pptx

Notes de l'éditeur

  1. The linker histone H1 directs the path of DNA between the adjacent nucleosomes that make up the chromatin fiber
  2. This project is based upon our findings that different interdependent modifications might modulate the biological function of HDAC1, a class I histone deacetylase (Figure 2). Human HDACs are targets for cancer therapy. However, although the therapeutic efforts with HDAC inhibitors in the treatment of cancer are being pursued (Figure 3), the role of individual HDACs in tumor genesis remains to be elucidated. The overriding theme of our studies is to understand whether HDAC1 is a relevant target for tumor therapy. This is accompanied by a study aimed at determining the role of Class I HDACs and possibly Class II in the maintenance of tumors www.ifom-ieo-campus.it/research/chiocca.php
  3. Hydroxamic acid based differentiating and antiproliferative agents were among the first compounds to be identified as histone deacetylase inhibitors, and these agents helped to define the model pharmacophore for HDAC inhibitors. Hydroxamic-acid containing HDAC inhibitors have been postulated to interact with the catalytic site of HDACs, thereby blocking substrate access to the active zinc ion at its base
  4. This pharmacophore consists of a metal binding domain, which interacts with the active site, a linker domain, which occupies the channel, and a surface recognition domain, which interacts with residues on the edge of the active site The linker domain can consist of linear or cyclic structures, either saturated or unsaturated, and the surface recognition domain is generally a hydrophobic group, most often aromatic.
  5. SAHA is the first HDAC inhibitor to meet FDA approval for cancer treatment. The HDAC inhibitor SAHA was reported by Breslow and co-workers. An important feature of SAHA is its ability to chelate the zinc ion in the active site through its CO and OH groups. SAHA may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SAHA inhibits HDAC activity by binding to the pocket of the catalytic site. The hydroxamic acid moiety of SAHA binds to a zinc atom (pink) allowing the rest of the molecule to lie along the surface of the HDLP protein At this point inhibits histone deacetylase, an enzyme that compacts chromatin and represses gene transcription, by binding to its active site. This allows histone acetyltransferase to activate gene transcription by catalyzing the addition of acetyl groups to the amino tails of the nucleosome, resulting in chromatin uncoiling and activation of gene transcription